CN109790123A - 新型衣壳蛋白装配抑制剂 - Google Patents

新型衣壳蛋白装配抑制剂 Download PDF

Info

Publication number
CN109790123A
CN109790123A CN201780055155.7A CN201780055155A CN109790123A CN 109790123 A CN109790123 A CN 109790123A CN 201780055155 A CN201780055155 A CN 201780055155A CN 109790123 A CN109790123 A CN 109790123A
Authority
CN
China
Prior art keywords
alkyl
amino
yuan
base
dichloropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780055155.7A
Other languages
English (en)
Other versions
CN109790123B (zh
Inventor
张寅生
敖汪伟
李元
沈杭州
柳英帅
李东旭
刘保民
王辉
陆鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202110806054.7A priority Critical patent/CN113429341A/zh
Publication of CN109790123A publication Critical patent/CN109790123A/zh
Application granted granted Critical
Publication of CN109790123B publication Critical patent/CN109790123B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明属于药物化学领域，涉及一种新型衣壳蛋白装配抑制剂，具体而言，涉及式I所示的化合物、其立体异构体或其药学上可接受的盐、制备方法、药物组合物及医药用途，包括用于治疗受益于衣壳蛋白装配抑制的疾病的用途，尤其是乙型肝炎病毒感染引起的疾病，其中，通式I中A、M、L、D的定义与说明书的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780055155.7A 2016-09-18 2017-09-18 新型衣壳蛋白装配抑制剂 Active CN109790123B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110806054.7A CN113429341A (zh) 2016-09-18 2017-09-18 新型衣壳蛋白装配抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016108293705 2016-09-18
CN201610829370 2016-09-18
PCT/CN2017/102054 WO2018050110A1 (zh) 2016-09-18 2017-09-18 新型衣壳蛋白装配抑制剂

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110806054.7A Division CN113429341A (zh) 2016-09-18 2017-09-18 新型衣壳蛋白装配抑制剂

Publications (2)

Publication Number Publication Date
CN109790123A true CN109790123A (zh) 2019-05-21
CN109790123B CN109790123B (zh) 2021-06-25

Family

ID=61619342

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110806054.7A Pending CN113429341A (zh) 2016-09-18 2017-09-18 新型衣壳蛋白装配抑制剂
CN201780055155.7A Active CN109790123B (zh) 2016-09-18 2017-09-18 新型衣壳蛋白装配抑制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110806054.7A Pending CN113429341A (zh) 2016-09-18 2017-09-18 新型衣壳蛋白装配抑制剂

Country Status (2)

Country Link
CN (2) CN113429341A (zh)
WO (1) WO2018050110A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019185016A1 (zh) 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途
EA202092159A1 (ru) * 2019-01-25 2020-12-15 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение
TW202138352A (zh) * 2019-12-20 2021-10-16 美商愛彼特生物製藥股份有限公司 經取代之雙環及三環脲類及醯胺類、其類似物及使用其之方法
CN115677680A (zh) * 2021-07-23 2023-02-03 上海挚盟医药科技有限公司 式i化合物的晶型及其制备和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073774A1 (en) * 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683817B1 (fr) * 1991-11-18 1994-02-25 Upsa Laboratoires Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4306873A1 (de) * 1993-03-05 1994-09-08 Boehringer Mannheim Gmbh Neue 4-Aminopyridine-Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073774A1 (en) * 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS.REGISTRY DATABASE: "RN号为1317856-61-3、1315815-31-6、1567329-76-3、1798008-58-8、1808761-81-0、1394584-64-5的化合物", 《STNEXT》 *
ACS.REGISTRY DATABASE: "RN号为1965628-52-7、1919976-19-4、1798713-55-9、1783274-76-9、1783152-93-1、1783149-26-7、1783103-00-3、1783035-81-3、1510167-04-0、1496674-20-4、1424544-51-3、1332170-71-4、1331979-02-2的化合物", 《STNEXT》 *

Also Published As

Publication number Publication date
WO2018050110A1 (zh) 2018-03-22
CN109790123B (zh) 2021-06-25
CN113429341A (zh) 2021-09-24

Similar Documents

Publication Publication Date Title
CN109790123A (zh) 新型衣壳蛋白装配抑制剂
CA3001666C (en) Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CA2987570C (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ES2660210T3 (es) Derivados de indolcarboxamida y usos de los mismos
AU2006237365B2 (en) 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
CN103097359A (zh) 新化合物
Lu et al. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease
CN110041327A (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
JP6591698B2 (ja) 新規なｎ−［（ピリミジニルアミノ）プロパニル］−およびｎ−［（ピラジニルアミノ）プロパニル］アリールカルボキサミド
Xie et al. Synthesis and antiviral/fungicidal/insecticidal activities study of novel chiral indole diketopiperazine derivatives containing acylhydrazone moiety
CN102216279A (zh) 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
TW200911744A (en) New compounds
CN102170882B (zh) 治疗淀粉状蛋白疾病的组合物和其制药用途
JP2009500335A (ja) ヒスタミンｈ３受容体薬剤、製剤及び治療的使用
US10550080B2 (en) Acyl sulfonamide NaV1.7 inhibitors
US8288398B2 (en) Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones
WO2023070114A2 (en) Reversible lysine covalent modifiers of egfr and uses thereof
JP2020528460A (ja) 新規なｎ−［（ピリミジニルアミノ）プロパニル］−、ｎ−［（ピリジルアミノ）プロパニル］−およびｎ−［（ピラジニルアミノ）プロパニル］アリールカルボキサミド
CN106795100B (zh) 化合物、药物组合物及其在治疗神经退行性疾病中的用途
CN101077866B (zh) 取代苯并噁唑类抗真菌化合物及其制备方法
CN105085410B (zh) 一种二芳基嘧啶类hiv‑1抑制剂及其制备方法
CA2887420C (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
JP2018503683A (ja) ピロールアミド系化合物、その製造方法、及び用途
CN108290904A (zh) 氘修饰的elbasvir 衍生物、含有该化合物的药物组合物及其用途
TW200800905A (en) Substituted 1-amino-4-phenyldihydroisoquinolines, process for their preparation, their use as medicament, and medicament comprising them

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant